International cohort studies suggest that adding azithromycin to hydroxychloroquine (HCQ) treatment may increase heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length of ECG. Severe adverse events associated with HCQ-azithromycin were compared to HCQ-amoxicillin in rheumatoid arthritis patients aged 18+ and followed up over 30 days. A total of 323,122 and 351,956 users of HCQ-azithromycin and HCQ-amoxicillin were included. When azithromycin was added to HCQ, an increased risk of 30-day cardiovascular mortality (HR2.19), chest pain/angina (HR 1.15), and heart failure (HR 1.22) were observed. HCQ is a drug for malarial and for systemic lupus erythematosus. It recently received Emergency Use Authorization by the FDA for use to treat COVID-19 patients. Source: https://www.medrxiv.org/
A US prospective study found that moderate egg consumption was associated with a significantly lower…
Anxiety disorders are common yet often underrecognized in primary care, but a review shows that…
Two-dose recombinant zoster vaccination (RZV) was associated with a significantly lower risk of new-onset dementia,…
A 13-year follow-up of a randomized controlled trial found that a single colonoscopy screening significantly…
Higher consumption of ultra-processed foods (UPFs) is associated with poorer attention and increased modifiable dementia…
Blood pressure (BP)-lowering treatment significantly reduces the risk of major cardiovascular events in individuals with…
This website uses cookies.